Screener Summaries Updates Institutions Sign In More Updates › Other Events › KAPA Other Events · Jul 15, 2026
Kairos Pharma, Ltd. issued a press release on July 15, 2026, reporting interim safety data from its ongoing Phase 1… KAPA Kairos Pharma, Ltd.
Kairos Pharma, Ltd. issued a press release on July 15, 2026, reporting interim safety data from its ongoing Phase 1 clinical trial for ENV-105 (Carotuximab) in combination with osimertinib for patients with advanced EGFR-mutated non-small cell lung cancer. Kairos Pharma, Ltd. is a pharmaceutical company focused on developing clinical-stage drug candidates.
More from Kairos Pharma, Ltd. Kairos Pharma wins Biotech Breakthrough Award for Cancer Immunology Solution of the Year Nov 5, 2026 Kairos Pharma reports positive interim Phase 2 data for ENV-105 in prostate cancer, median PFS of 17.7 months Oct 6, 2026 Kairos Pharma, Ltd. announced that its Board authorized a one-for-seven reverse stock split of its common stock… Aug 21, 2026 Kairos Pharma, Ltd. entered into an Investigator/Institution Initiated Research (IIR) Agreement with Bayer HealthCare… Jul 22, 2026 At its June 29, 2026 annual meeting, Kairos Pharma Ltd. stockholders approved an amendment to the certificate of… Jun 30, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
